-+ 0.00%
-+ 0.00%
-+ 0.00%
Palvella Therapeutics unveils QTORIN docetaxel program for extramammary Paget’s disease
Share
Listen to the news
Palvella Therapeutics unveils QTORIN docetaxel program for extramammary Paget’s disease
  • Palvella Therapeutics announced QTORIN docetaxel on November 19, 2026, as a topical treatment candidate for extramammary Paget’s disease.
  • IND-enabling activities have begun, with an FDA meeting planned for the first half of 2027 before a Phase 2 study starts.
  • The program builds on clinical evidence from intravenous docetaxel, aiming to offer localized treatment instead of repeated, disfiguring surgeries.
  • EMPD affects more than 10,000 U.S. patients; the candidate could become the disease’s first FDA-approved therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611190730PRIMZONEFULLFEED9881117) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending